BMEA
Biomea Fusion, Inc.
1W: -16.2%
1M: -13.6%
3M: -15.6%
YTD: -14.9%
1Y: -58.2%
3Y: -92.6%
$1.14
+0.05 (+4.59%)
After Hours: $1.22 (+0.08, +7.02%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$67.8M
52W Range0.872-3.08
Volume981,988
Avg Volume1,083,825
Beta-0.21
Dividend—
Analyst Ratings
Company Info
CEOMichael J. Hitchcock
Employees79
SectorHealthcare
IndustryBiotechnology
IPO Date2021-04-16
Websitebiomeafusion.com
900 Middlefield Road
Redwood City, CA 94063
US
Redwood City, CA 94063
US
650 980 9099
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Latest News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Biomea Fusion Spotlights Diabetes, Obesity Pipeline at JPMorgan Conference, Sets 2026 Milestones
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Erdtmann Rainer M | 0 | — | 2025-12-31 | |
| Erdtmann Rainer M | 0 | — | 2025-12-31 | |
| Erdtmann Rainer M | P-Purchase | 30,000 | $1.43 | 2025-12-11 |
| Hitchcock Michael J. | P-Purchase | 100,000 | $0.99 | 2025-12-02 |
| Erdtmann Rainer M | P-Purchase | 10,000 | $1.05 | 2025-12-01 |